{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-25-000045","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.428315+00:00","generated_at":"2026-05-22T12:52:16.231349+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Krystal Biotech Q1 VYJUVEK revenue $88.2M; net income $35.7M; EU approval secured","bullets":["VYJUVEK net product revenue $88.2M in Q1 2025 (vs $45.3M Q1 2024); gross margin 94%.","Net income $35.7M ($1.24 basic EPS) vs $0.9M ($0.03) year ago; cash $765.3M.","European Commission approved VYJUVEK for DEB; first Germany launch mid-2025; Japan decision expected 2H2025.","Second ophthalmic program KB801 IND cleared for neurotrophic keratitis; Phase 1/2 EMERALD-1 starts May 2025.","FY2025 non-GAAP R&D+SG&A guidance $150-175M; upcoming readouts for CF, AATD, ocular DEB, aesthetics."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-25-000045","json":"https://secwatch.observer/filing/0001711279-25-000045.json","markdown":"https://secwatch.observer/filing/0001711279-25-000045.md","text":"https://secwatch.observer/filing/0001711279-25-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000045/0001711279-25-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127925000045/krys-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T12:52:16.231349+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}